Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $49.71 billion. The enterprise value is $79.92 billion.
Important Dates
The next confirmed earnings date is Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Sep 30, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has decreased by -1.89% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | -1.89% |
| Shares Change (QoQ) | -1.58% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 50.37% |
| Float | 1.58B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 50.66 |
| PS Ratio | 1.75 |
| Forward PS | 0.01 |
| PB Ratio | 1.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.29 |
| P/OCF Ratio | 7.59 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.28, with an EV/FCF ratio of 14.94.
| EV / Earnings | n/a |
| EV / Sales | 2.82 |
| EV / EBITDA | 10.28 |
| EV / EBIT | 20.91 |
| EV / FCF | 14.94 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.09 |
| Quick Ratio | 0.52 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 4.26 |
| Debt / FCF | 6.44 |
| Interest Coverage | 4.10 |
Financial Efficiency
Return on equity (ROE) is -2.12% and return on invested capital (ROIC) is 4.92%.
| Return on Equity (ROE) | -2.12% |
| Return on Assets (ROA) | 2.55% |
| Return on Invested Capital (ROIC) | 4.92% |
| Return on Capital Employed (ROCE) | 4.79% |
| Weighted Average Cost of Capital (WACC) | 3.67% |
| Revenue Per Employee | $602,542 |
| Profits Per Employee | -$20,379 |
| Employee Count | 47,029 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $61.44 million in taxes.
| Income Tax | 61.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.28% in the last 52 weeks. The beta is 0.09, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +6.28% |
| 50-Day Moving Average | 16.22 |
| 200-Day Moving Average | 16.02 |
| Relative Strength Index (RSI) | 50.55 |
| Average Volume (20 Days) | 2,974,138 |
Short Selling Information
The latest short interest is 4.88 million, so 0.31% of the outstanding shares have been sold short.
| Short Interest | 4.88M |
| Short Previous Month | 5.00M |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 1.54 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $28.34 billion and -$958.40 million in losses. Loss per share was -$0.61.
| Revenue | 28.34B |
| Gross Profit | 18.15B |
| Operating Income | 3.82B |
| Pretax Income | -895.29M |
| Net Income | -958.40M |
| EBITDA | 7.78B |
| EBIT | 3.82B |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $3.74 billion in cash and $34.44 billion in debt, giving a net cash position of -$30.70 billion or -$19.43 per share.
| Cash & Cash Equivalents | 3.74B |
| Total Debt | 34.44B |
| Net Cash | -30.70B |
| Net Cash Per Share | -$19.43 |
| Equity (Book Value) | 46.73B |
| Book Value Per Share | 29.58 |
| Working Capital | 1.63B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.55 billion and capital expenditures -$1.11 billion, giving a free cash flow of $5.35 billion.
| Operating Cash Flow | 6.55B |
| Capital Expenditures | -1.11B |
| Depreciation & Amortization | 3.89B |
| Net Borrowing | 6.65M |
| Free Cash Flow | 5.35B |
| FCF Per Share | $3.39 |
Full Cash Flow StatementMargins
Gross margin is 64.06%, with operating and profit margins of 13.49% and -3.38%.
| Gross Margin | 64.06% |
| Operating Margin | 13.49% |
| Pretax Margin | -3.16% |
| Profit Margin | -3.38% |
| EBITDA Margin | 27.44% |
| EBIT Margin | 13.49% |
| FCF Margin | 18.88% |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 1.58%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 1.58% |
| Dividend Growth (YoY) | 4.37% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 1.89% |
| Shareholder Yield | 3.47% |
| Earnings Yield | -1.93% |
| FCF Yield | 10.76% |
Dividend DetailsAnalyst Forecast
The average price target for Takeda Pharmaceutical is $20.63, which is 29.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.63 |
| Price Target Difference | 29.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 2.23% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.04 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.04 |
| Piotroski F-Score | 4 |